Adding serum biomarkers to biannual ultrasound in patients at high risk for hepatocellular carcinoma may not improve the early detection of the condition. Medscape Medical News
We scan the top radiology sources so you don’t have to.
From AI breakthroughs to imaging trends, we serve up real-time radiology insights.
-
Paradigm Shift for Evaluating, Treating Biochemical Recurrence in Prostate Cancer
(MedPage Today) — Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen (PSMA) PET/CT, a retrospective…
-
Digital X-ray Market Worth $7.50 Billion by 2031 | MarketsandMarkets™
According to MarketsandMarkets™, the Digital X-ray Market is estimated to reach USD 7.50 billion by 2031 from USD 5.76 billion in 2025, at a CAGR of 4.5%.Browse 200 market data Tables and 40 Figures spread through 300 Pages and in-depth TOC on ‘Digital X-ray Market – Global Forecast to 2031’Digital X-ray Size & Forecast:Market Size Available for […]
Source -
U.K. Cancer Doctors Respond to Cancer Plan for England
Cancer plan reflects Royal College of Radiologists’ priorities for improving cancer care. The Royal College of Radiologists (RCR) has issued its initial reaction to the British government’s recently-released National Cancer Plan for England. The Plan reflects priorities long highlighted by the RCR, the body representing senior doctors responsible for cancer diagnosis and treatment, to: Embrace supportive oncology Reform multidisciplinary team meetings (MDTMs) Plan for the rollout of innovative…
-
Which Interferon Is More Relevant in RA: Alfa or Gamma?
Higher serum levels of interferon alfa, but not interferon gamma, are tied to worse disease activity in patients with rheumatoid arthritis; however, neither is linked to cardiovascular risk. Medscape News UK
-
New Ultrasound Model Boosts Early Ovarian Cancer Detection
Ultrasound with the International Ovarian Tumour Analysis model at 10% yields better sensitivity than the standard risk prediction tool in triaging premenopausal women for early ovarian cancer. Medscape News UK